Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA approved its generic version of Novo Nordisk’s (NVO) Saxenda (liraglutide injection), a GLP-1 weight loss drug.
“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva.
Liraglutide injection is indicated for adults and pediatric patients (12-17 years) with obesity to help them lose weight and keep the weight off.
